A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors

Summary

This is a first-in-human Phase Ia/Ib, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and maximum tolerated dose (MTD) or maximum adminstered dose (MAD) of BPT567 in patients with advanced solid tumors, and establish the recommended dose for expansion cohorts.

Timeline

Start

2024-10-15

Primary completion

2026-01-21

Completion

2026-03-11

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Drugs

Indications